Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/25722
Title: | RET-Rearranged Lung Cancer |
Authors: | SANTINI, Fernando C.; KATZ, Artur |
Citation: | AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, v.13, n.12, p.32-37, 2017 |
Abstract: | In recent years, we have witnessed the discovery of several oncogenic driver mutations as well as the emergence of specific inhibitors with high response rates and few treatment-related adverse events. RET-rearranged lung cancers represent a small subset of lung cancer, most commonly encountered in patients with adenocarcinoma and minimal or no exposure to tobacco. Several multikinase inhibitors have been tested with high ""off-target"" toxicity and low RET inhibition activity. Early-phase clinical trials with more selective inhibitors are awaited. Here, we review the main aspects of the biology of RET, the challenges of RET inhibition in lung cancer, and some future perspectives. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICESP |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_SANTINI_RETRearranged_Lung_Cancer_2017.PDF Restricted Access | publishedVersion (English) | 619.34 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.